½ÃÀ庸°í¼­
»óǰÄÚµå
1358156

ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀå : Á¦Ç° À¯Çüº°, Åõ¿© °æ·Îº°, À¯Åë ä³Îº°, Áö¿ªº°

Interferon Beta Drugs Market, By Product Type, By Route Of Administration, By Distribution Channel, By Geography

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: Coherent Market Insights | ÆäÀÌÁö Á¤º¸: ¿µ¹® | ¹è¼Û¾È³» : 2-3ÀÏ (¿µ¾÷ÀÏ ±âÁØ)

    
    
    




¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

¼¼°èÀÇ ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀå ±Ô¸ð´Â 2023³â¿¡ 42¾ï 2,000¸¸ ´Þ·¯·Î ÃßÁ¤µÇ¸ç, ¿¹Ãø ±â°£ Áß(2023-2030³â) CAGRÀº 4.0%·Î ¿¹ÃøµË´Ï´Ù.

¸®Æ÷Æ® ´ë»ó ¹üÀ§ ¸®Æ÷Æ® »ó¼¼
±âÁسâ 2022³â 2023³â ½ÃÀå ±Ô¸ð 42¾ï 2,000¸¸ ´Þ·¯
½ÇÀû µ¥ÀÌÅÍ 2018-2021³â ¿¹Ãø ±â°£ 2023-2030
¿¹Ãø ±â°£ CAGR 4.00% 2030³â ½ÃÀå ±Ô¸ð ¿¹Ãø 55¾ï 5,000¸¸ ´Þ·¯
¼¼°èÀÇ ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀå Á¡À¯À²(%), Á¦Ç° À¯Çüº°, 2023³â
Interferon Beta Drugs Market-IMG1

ÀÎÅÍÆä·Ð º£Å¸´Â ÀÓ»óÀû ºÐ¸® ÁõÈıº, Àç¹ß¼º ¿ÏÈ­Çü Áúȯ, Ȱµ¿¼º ÀÌÂ÷ ÁøÇ༺ Áúȯ°ú °°Àº Àç¹ß¼º ´Ù¹ß¼º °æÈ­Áõ(MS)ÀÇ Ä¡·á¿¡ »ç¿ëµË´Ï´Ù. ÀÌ ¾àÀº º´À» ¿ÏÀüÈ÷ Ä¡·áÇÏÁö´Â ¾ÊÁö¸¸, Àå¾Ö¸¦ À¯¹ßÇÏ´Â ÀϺΠÁõ»óÀÇ ÁøÇàÀ» ´ÊÃß°í Àç¹ß Ƚ¼ö¸¦ ÁÙÀÔ´Ï´Ù. ÀÎÅÍÆä·ÐÀº °¨¿°¿¡ ´ëÇ×Çϱâ À§ÇØ ÀÎü¿¡¼­ »ý¼ºµÇ´Â õ¿¬ ¹°ÁúÀÔ´Ï´Ù. ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦´Â ÀÎÅÍÆä·Ð º£Å¸-1A, ÀÎÅÍÆä·Ð º£Å¸-1B, Æä±×ÀÎÅÍÆä·Ð º£Å¸-1A·Î ³ª´¹´Ï´Ù.

½ÃÀå ¿ªÇÐ

´Ù¹ß¼º °æÈ­ÁõÀº ±¤¹üÀ§ÇÑ Àå¾Ö¸¦ À¯¹ßÇÏ´Â ½Å°æ ÁúȯÀ¸·Î, ´ëºÎºÐ 20-50´ë¿¡ ¹ßº´ÇÕ´Ï´Ù. ´Ù¹ß¼º °æÈ­Áõ ȯÀÚ¿Í °¡Á·À» À§ÇÑ 501°³ ºñ¿µ¸® ´ÜüÀÎ ´Ù¹ß¼º °æÈ­Áõ Àç´Ü¿¡ µû¸£¸é 2020³â 1¿ù ±âÁØ ÀÌ ÀÚ°¡¸é¿ªÁúȯÀº 2,500¸¸ ¸í¿¡°Ô ¿µÇâÀ» ¹ÌÄ¡°í ÀÖÀ¸¸ç, ¼¼°è ¿¬°£ ¹ßº´·üÀº Àα¸ 10¸¸ ¸í´ç ¾à 7¸íÀÔ´Ï´Ù. ¶ÇÇÑ À¯º´·üÀº ÀÎÁ¾°ú Áö¿ªÀû À§µµ¿¡ µû¶ó Àα¸ 10¸¸ ¸í´ç 50¸í¿¡¼­ 120¸í »çÀÌ·Î ´Ù¾çÇÏ´Ù°í ¹àÇû½À´Ï´Ù. ¶ÇÇÑ ´Ù¹ß¼º °æÈ­Áõ Àç´ÜÀÌ 2021³â ¹ßÇ¥ÇÑ µ¥ÀÌÅÍ¿¡ µû¸£¸é ¹Ì±¹¿¡¼­´Â ¾à 40¸¸ ¸íÀÌ ÀÌ ÁúȯÀ» ¾Î°í ÀÖÀ¸¸ç, ¸ÅÁÖ ¾à 200¸íÀÌ »õ·Î Áø´ÜÀ» ¹Þ°í ÀÖ´Ù°í ÇÕ´Ï´Ù. ´Ù¹ß¼º °æÈ­ÁõÀº ¿ïÇ÷¼º ½ÉºÎÀü¿¡ ÀÌ¾î µÎ ¹øÂ°·Î Å« Áúº´À¸·Î, ȯÀÚ 1ÀÎ´ç ¿¬°£ 8,528´Þ·¯¿¡¼­ 54,244´Þ·¯ÀÇ Á÷°£Á¢Àû ÀÇ·áºñ¿ëÀÌ ¼Ò¿äµË´Ï´Ù. ÀÌó·³ ´Ù¹ß¼º °æÈ­ÁõÀÇ À¯º´·ü Áõ°¡´Â ¼¼°è ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀåÀÇ ¼ºÀåÀ» °¡¼ÓÇÏ´Â ÁÖ¿ä ¿äÀÎÀ¸·Î ÀÛ¿ëÇϰí ÀÖ½À´Ï´Ù.

º» Á¶»çÀÇ ÁÖ¿ä Æ¯Â¡

  • ¼¼°èÀÇ ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀåÀ» »ó¼¼ ºÐ¼®Çϰí, 2022³âÀ» ±âÁسâÀ¸·Î ÇÑ ¿¹Ãø ±â°£(2023-2030³â)ÀÇ ½ÃÀå ±Ô¸ð ¹× CAGRÀ» Á¦°øÇÕ´Ï´Ù.
  • ¶ÇÇÑ ´Ù¾çÇÑ ºÎ¹®ÀÇ ÀáÀçÀû ¸ÅÃâ ±âȸ¸¦ ¼³¸íÇϰí, ÀÌ ½ÃÀå¿¡ ´ëÇÑ ¸Å·ÂÀûÀÎ ÅõÀÚ Á¦¾È ¸ÅÆ®¸¯½º¿¡ ´ëÇØ ÇØ¼³Çϰí ÀÖ½À´Ï´Ù.
  • ¶ÇÇÑ ½ÃÀå ÃËÁø¿äÀÎ, ¾ïÁ¦¿äÀÎ, ±âȸ, ½ÅÁ¦Ç° Ãâ½Ã ¹× ½ÂÀÎ, ½ÃÀå µ¿Çâ, Áö¿ªº° Àü¸Á, ÁÖ¿ä ±â¾÷ÀÌ Ã¤ÅÃÇÏ´Â °æÀï Àü·« µî¿¡ °üÇÑ ÁÖ¿ä ÀλçÀÌÆ®µµ Á¦°øÇϰí ÀÖ½À´Ï´Ù.
  • ±â¾÷ ÇÏÀ̶óÀÌÆ®, Á¦Ç° Æ÷Æ®Æú¸®¿À, ÁÖ¿ä ÇÏÀ̶óÀÌÆ®, À繫 ½ÇÀû, Àü·« µîÀÇ ÆÄ¶ó¹ÌÅÍ¿¡ ±â¹ÝÇÏ¿© ¼¼°èÀÇ ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀåÀÇ ÁÖ¿ä ±â¾÷À» ÇÁ·ÎÆÄÀϸµÇϰí ÀÖ½À´Ï´Ù.
  • º» ¸®Æ÷Æ®·ÎºÎÅÍÀÇ ÀλçÀÌÆ®¿¡ ÀÇÇØ ¸¶ÄÉÆÃ ´ã´çÀÚ ¹× ±â¾÷ÀÇ °æ¿µÁøÀº ÇâÈÄ Á¦Ç° ¹ß¸Å, À¯Çü ¾÷±×·¹À̵å, ½ÃÀå È®´ë, ¸¶ÄÉÆÃ Àü¼ú¿¡ °üÇÑ Á¤º¸¿¡ ±â¹ÝÇÑ ÀÇ»ç°áÁ¤À» ½ÃÇàÇÒ ¼ö ÀÖ½À´Ï´Ù.
  • ¼¼°èÀÇ ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀå ¸®Æ÷Æ®´Â ÅõÀÚÀÚ, °ø±Þ¾÷ü, Á¦Ç° Á¦Á¶¾÷ü, À¯Åë¾÷ü, ½Å±Ô Âü¿©¾÷ü, À繫 ¾Ö³Î¸®½ºÆ® µî ÀÌ ¾÷°èÀÇ ´Ù¾çÇÑ ÀÌÇØ°ü°èÀÚ¸¦ ´ë»óÀ¸·Î Çϰí ÀÖ½À´Ï´Ù.
  • ÀÌÇØ°ü°èÀÚ´Â ¼¼°èÀÇ ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀå ºÐ¼®¿¡ »ç¿ëµÇ´Â ´Ù¾çÇÑ Àü·« ¸ÅÆ®¸¯½º¸¦ ÅëÇØ ÀÇ»ç°áÁ¤À» ¿ëÀÌÇÏ°Ô ÇÒ ¼ö ÀÖ½À´Ï´Ù.

¸ñÂ÷

Á¦1Àå Á¶»çÀÇ ¸ñÀû°ú ÀüÁ¦

  • Á¶»çÀÇ ¸ñÀû
  • °¡Á¤
  • ¾à¾î

Á¦2Àå ½ÃÀå Àü¸Á

  • ¸®Æ÷Æ® ¼³¸í
    • ½ÃÀåÀÇ Á¤ÀÇ¿Í ¹üÀ§
  • ÁÖ¿ä ¿ä¾à
  • Coherent Opportunity Map(COM)

Á¦3Àå ½ÃÀå ¿ªÇÐ, ±ÔÁ¦, µ¿Ç⠺м®

  • ½ÃÀå ¿ªÇÐ
    • ÃËÁø¿äÀÎ
    • ¾ïÁ¦¿äÀÎ
    • ½ÃÀå ±âȸ
  • ¿µÇ⠺м®
  • ÃÖ±Ù Á¦Ç° ¹ß¸Å
  • ¿ªÇÐ
  • ÇÕº´, Àμö ¹× Çù¾÷
  • ±ÔÁ¦ ½Ã³ª¸®¿À
  • ÁÖ¿ä ¹ßÀü
  • PEST ºÐ¼®

Á¦4Àå ¼¼°èÀÇ ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀå, COVID-19ÀÇ ¿µÇ⠺м®

  • °æÁ¦Àû ¿µÇâ
  • ½ÅÁ¾ Äڷγª¹ÙÀÌ·¯½º(COVID-19) ¿ªÇÐ
  • ¼ö¿ä¿Í °ø±Þ¿¡ ´ëÇÑ ¿µÇâ

Á¦5Àå ¼¼°èÀÇ ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀå, Á¦Ç° À¯Çüº°, 2018-2030³â

  • ÀÎÅÍÆä·Ð º£Å¸-1A
  • ÀÎÅÍÆä·Ð º£Å¸-1B
  • Æä±×ÀÎÅÍÆä·Ð º£Å¸-1A

Á¦6Àå ¼¼°èÀÇ ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀå, Åõ¿© °æ·Îº°, 2018-2030³â

  • ±ÙÀ°³»
  • ÇÇÇÏ
  • Á¤¸Æ³»

Á¦7Àå ¼¼°èÀÇ ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀå, À¯Åë ä³Îº°, 2018-2030³â

  • º´¿ø ¾à±¹
  • ¼Ò¸Å ¾à±¹
  • ¿Â¶óÀÎ ¾à±¹

Á¦8Àå ¼¼°èÀÇ ÀÎÅÍÆä·Ð º£Å¸ Á¦Á¦ ½ÃÀå, Áö¿ªº°, 2018-2030³â

  • ºÏ¹Ì
  • ¹Ì±¹
  • ij³ª´Ù
  • ¶óƾ¾Æ¸Þ¸®Ä«
  • ºê¶óÁú
  • ¸ß½ÃÄÚ
  • ¾Æ¸£ÇîÆ¼³ª
  • ±âŸ ¶óƾ¾Æ¸Þ¸®Ä«
  • À¯·´
  • ¿µ±¹
  • µ¶ÀÏ
  • ÀÌÅ»¸®¾Æ
  • ÇÁ¶û½º
  • ½ºÆäÀÎ
  • ·¯½Ã¾Æ
  • ±âŸ À¯·´
  • ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áß±¹
  • Àεµ
  • ÀϺ»
  • ASEAN
  • È£ÁÖ
  • Çѱ¹
  • ±âŸ ¾Æ½Ã¾ÆÅÂÆò¾ç
  • Áßµ¿
  • GCC
  • À̽º¶ó¿¤
  • ±âŸ Áßµ¿
  • ¾ÆÇÁ¸®Ä«
  • ºÏ¾ÆÇÁ¸®Ä«
  • Áß¾Ó¾ÆÇÁ¸®Ä«
  • ³²¾ÆÇÁ¸®Ä«

Á¦9Àå °æÀï ±¸µµ

  • Biogen
  • Merck KGaA
  • Novartis AG
  • Bayer AG

Á¦10Àå ¼½¼Ç

  • Á¶»ç ¹æ¹ý
  • ÃâÆÇ»ç ¼Ò°³
KSA 23.10.26

The global interferon beta drugs market is estimated to be valued at US$ 4.22 Bn in 2023 and is expected to exhibit a CAGR of 4.0% during the forecast period (2023-2030).

Report Coverage Report Details
Base Year: 2022 Market Size in 2023: US$ 4.22 Bn
Historical Data for: 2018 to 2021 Forecast Period: 2023 - 2030
Forecast Period 2023 to 2030 CAGR: 4.00% 2030 Value Projection: US$ 5.55 Bn
Global Interferon Beta Drugs Market Share (%), by Product Type, 2023
Interferon Beta Drugs Market - IMG1

Interferon beta is used to treat relapsing forms of multiple sclerosis (MS), including clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The drug does not completely cure the condition, but it slows down the progression of some of the disabling effects and decreases the number of relapses. Interferons are natural substances produced in the human body to help fight infections. Interferon beta drugs are categorized as Interferon Beta-1A, Interferon Beta-1B, and Peginterferon Beta-1A.

Market Dynamics

Multiple sclerosis is a widespread disabling neurological condition, mostly diagnosed in people in the age group of 20-50 years. According to the Multiple Sclerosis Foundation, a 501 non-profit organization benefiting people with multiple sclerosis and their families, in January 2020, this autoimmune condition affected 2.5 million people with an annual global incidence of around 7 cases per 100,000 people. The study also states that prevalence rates vary between ethnic and geographical latitudes, ranging from 50 to 120 people per 100,000. Moreover, according to the data published by the Multiple Sclerosis Foundation in 2021, an estimated 400,000 people live with the disease in the U.S., and about 200 new cases are diagnosed every week. According to a survey by Healthline Media, a provider of health information headquartered in California, U.S., in March 2022, multiple sclerosis ranks second after congestive heart failure, with direct and indirect health care costs ranging from US$8,528 to US$54,244 per patient per year. Thus, the increasing prevalence of multiple sclerosis is a major factor driving the growth of the global interferon beta drugs market.

Key features of the study:

  • This report provides an in-depth analysis of the global interferon beta drugs market and provides market size (US$ Bn) and compound annual growth rate (CAGR) for the forecast period (2023-2030), considering 2022 as the base year
  • It elucidates potential revenue opportunities across different segments and explains attractive investment proposition matrices for this market
  • This study also provides key insights about market drivers, restraints, opportunities, new product launches or approval, market trends, regional outlook, and competitive strategies adopted by key players
  • It profiles key players in the global interferon beta drugs market based on the following parameters-Company highlights, products portfolio, key highlights, financial performance, and strategies
  • Key companies covered as a part of this study include Biogen, Merck KGaA, Novartis AG and Bayer AG.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decisions regarding their future product launches, type up-gradation, market expansion, and marketing tactics
  • Global interferon beta drugs market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
  • Stakeholders would have ease in decision-making through various strategy matrices used in analyzing the global interferon beta drugs market.

Detailed Segmentation:

  • Global Interferon Beta Drugs Market, By Product Type:
    • Interferon Beta-1A
    • Interferon Beta-1B
    • Peginterferon Beta-1A
  • Global Interferon Beta Drugs Market, By Route of Administration:
    • Intramuscular
    • Subcutaneous
    • Intravenous
  • Global Interferon Beta Drugs Market, By Distribution Channel:
    • Hospitals Pharmacies
    • Retail Pharmacies
    • Online Pharmacies
  • Global Interferon Beta Drugs Market, By Region:
    • North America
    • Europe
    • Asia-Pacific
    • Latin America

Middle East & Africa

  • Company Profiles
    • Biogen
    • Merck KGaA
    • Novartis AG
    • Bayer AG

Table of Contents

1. Research Objectives and Assumptions

  • Research Objectives
  • Assumptions
  • Abbreviations

2. Market Purview

  • Report Description
    • Market Definition and Scope
  • Executive Summary
    • Market Snapshot, By Product Type
    • Market Snapshot, By Route Of Administration
    • Market Snapshot, By Distribution Channel
    • Market Snapshot, By Region
  • Coherent Opportunity Map (COM)

3. Market Dynamics, Regulations, and Trends Analysis

  • Market Dynamics
    • Drivers
    • Restraints
    • Market Opportunities
  • Impact Analysis
  • Recent Product Launches
  • Epidemiology
  • Merger, Acquisition, and Collaborations
  • Regulatory Scenario
  • Key Developments
  • PEST Analysis

4. Global Interferon Beta Drugs Market- COVID-19 Impact Analysis

  • Economic Impact
  • COVID-19 Epidemiology
  • Impact on Supply and Demand

5. Global Interferon Beta Drugs Market, By Product Type, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Interferon Beta-1A
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Interferon Beta-1B
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Peginterferon Beta-1A
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

6. Global Interferon Beta Drugs Market, By Route Of Administration, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Intramuscular
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Subcutaneous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Intravenous
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

7. Global Interferon Beta Drugs Market, By Distribution Channel, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, 2018-2030
    • Segment Trends
  • Hospitals Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Retail Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)
  • Online Pharmacies
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, 2018-2030, (US$ Bn)

8. Global Interferon Beta Drugs Market, By Region, 2018-2030, (US$ Bn)

  • Introduction
    • Market Share Analysis, By Region, 2023 and 2030 (%)
    • Y-o-Y Growth Analysis, For Regions, 2018-2030
    • Regional Trends
  • North America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.S.
  • Canada
  • Latin America
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • Brazil
  • Mexico
  • Argentina
  • Rest of Latin America
  • Europe
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • U.K.
  • Germany
  • Italy
  • France
  • Spain
  • Russia
  • Rest of Europe
  • Asia Pacific
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • China
  • India
  • Japan
  • ASEAN
  • Australia
  • South Korea
  • Rest of Asia Pacific
  • Middle East
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Country, 2018-2030, (US$ Bn)
  • GCC
  • Israel
  • Rest of Middle East
  • Africa
    • Introduction
    • Market Size and Forecast, and Y-o-Y Growth, By Product type, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Route Of Administration , 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Distribution Channel, 2018-2030, (US$ Bn)
    • Market Size and Forecast, and Y-o-Y Growth, By Region/Country, 2018-2030, (US$ Bn)
  • North Africa
  • Central Africa
  • South Africa

9. Competitive Landscape

  • Biogen
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Merck KGaA
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Novartis AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies
  • Bayer AG
    • Company Highlights
    • Product Portfolio
    • Key Highlights
    • Financial Performance
    • Market Strategies

10. Section

  • Research Methodology
  • About Us
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦